132 related articles for article (PubMed ID: 10470197)
1. Comparison of the tumor associated proteases cathepsin D (CATH D) and urokinase-type plasminogen activator (uPA) in cytosols of human breast cancer patients.
Liebert A; Quietzsch D; Beier L
Anticancer Res; 1999; 19(4A):2571-6. PubMed ID: 10470197
[TBL] [Abstract][Full Text] [Related]
2. Prognostic value of p53 and urokinase-type plasminogen activator in node-negative human breast cancers.
Peyrat JP; Vanlemmens L; Fournier J; Huet G; Révillion F; Bonneterre J
Clin Cancer Res; 1998 Jan; 4(1):189-96. PubMed ID: 9516970
[TBL] [Abstract][Full Text] [Related]
3. Tumour-associated fibrinolysis: the prognostic relevance of plasminogen activators uPA and tPA in human breast cancer.
Schmitt M; Jänicke F; Graeff H
Blood Coagul Fibrinolysis; 1990 Dec; 1(6):695-702. PubMed ID: 2133250
[TBL] [Abstract][Full Text] [Related]
4. [The prognostic value of cathepsin D concentration in cytosol of primary breast carcinoma].
Bussen S; Rempen A; Caffier H
Zentralbl Gynakol; 1995; 117(5):253-9. PubMed ID: 7793167
[TBL] [Abstract][Full Text] [Related]
5. Comparative prognostic value of Cathepsin D and urokinase plasminogen activator, detected by immunohistochemistry, in primary breast carcinoma.
Göhring UJ; Scharl A; Thelen U; Ahr A; Crombach G
Anticancer Res; 1996; 16(2):1011-8. PubMed ID: 8687092
[TBL] [Abstract][Full Text] [Related]
6. Immunoenzymatic assay of Mr 52,000 cathepsin D in 182 breast cancer cytosols: low correlation with other prognostic parameters.
Maudelonde T; Khalaf S; Garcia M; Freiss G; Duporte J; Benatia M; Rogier H; Paolucci F; Simony J; Pujol H
Cancer Res; 1988 Jan; 48(2):462-6. PubMed ID: 3275497
[TBL] [Abstract][Full Text] [Related]
7. Cytosol cathepsin D in Thai women with breast cancer.
Chearskul S; Bhothisuwan K; Tunsuphasiri V; Churinthrapun M; Keyanond V; Ornrheabroi S
J Med Assoc Thai; 1996 Oct; 79(10):654-60. PubMed ID: 8997001
[TBL] [Abstract][Full Text] [Related]
8. Prognostic value of uPA and p53 accumulation measured by quantitative biochemical assays in 1245 primary breast cancer patients: a multicentre study.
Broët P; Spyratos F; Romain S; Quillien V; Daver A; Ricolleau G; Rallet A; Toulas C; Asselain B
Br J Cancer; 1999 May; 80(3-4):536-45. PubMed ID: 10408864
[TBL] [Abstract][Full Text] [Related]
9. Plasminogen activator inhibitor-1 and prognosis in primary breast cancer.
Foekens JA; Schmitt M; van Putten WL; Peters HA; Kramer MD; Jänicke F; Klijn JG
J Clin Oncol; 1994 Aug; 12(8):1648-58. PubMed ID: 8040677
[TBL] [Abstract][Full Text] [Related]
10. Complex of urokinase-type plasminogen activator with its type 1 inhibitor predicts poor outcome in 576 patients with lymph node-negative breast carcinoma.
Manders P; Tjan-Heijnen VC; Span PN; Grebenchtchikov N; Geurts-Moespot A; van Tienoven DT; Beex LV; Sweep FC
Cancer; 2004 Aug; 101(3):486-94. PubMed ID: 15274061
[TBL] [Abstract][Full Text] [Related]
11. Urokinase-type plasminogen activator, plasminogen activator inhibitor type 1 and cathepsin D: analysis of their prognostic significance in squamous cell carcinoma of the head and neck.
Strojan P; Budihna M; Smid L; Vrhovec I; Skrk J
Anticancer Res; 2000; 20(5C):3975-81. PubMed ID: 11268487
[TBL] [Abstract][Full Text] [Related]
12. [Expression of cathepsin D in breast cancer and its clinical and histopathological correlations].
Ramírez-Ortega MC; Frías-Mendívil M; Delgado-Chávez R; Meneses-García A; Carrillo-Hernández JF; Ramírez-Ugalde MT; Zeichner-Gancz I
Rev Invest Clin; 1997; 49(5):361-8. PubMed ID: 9527695
[TBL] [Abstract][Full Text] [Related]
13. Cathepsin D may help in discriminating node-negative breast cancer patients at risk for local-regional recurrence.
Ardavanis A; Scorilas A; Loukeri A; Gerakini F; Pissakas G; Missitzis I; Apostolikas N; Yiotis I
Anticancer Res; 1998; 18(4B):2885-90. PubMed ID: 9713481
[TBL] [Abstract][Full Text] [Related]
14. The urokinase system of plasminogen activation and prognosis in 2780 breast cancer patients.
Foekens JA; Peters HA; Look MP; Portengen H; Schmitt M; Kramer MD; Brünner N; Jänicke F; Meijer-van Gelder ME; Henzen-Logmans SC; van Putten WL; Klijn JG
Cancer Res; 2000 Feb; 60(3):636-43. PubMed ID: 10676647
[TBL] [Abstract][Full Text] [Related]
15. [Prognostic factors in breast cancer patients].
Roisman I; Peretz T; Reznick AZ; Lifshitz I; Bitterman A; Fares F; Toledano H; Barzilay A; Durst AL
Harefuah; 1996 May; 130(10):693-9. PubMed ID: 8794662
[No Abstract] [Full Text] [Related]
16. Determination of threshold values for determining the size of the fraction of steroid hormone receptor-positive tumor cells in paraffin-embedded breast carcinomas.
Leers MP; Hoop JG; van Beers M; van Rodijnen N; Pannebakker M; Nap M
Cytometry B Clin Cytom; 2005 Mar; 64(1):43-52. PubMed ID: 15668953
[TBL] [Abstract][Full Text] [Related]
17. [Breast cancer: prognostic value of a dissemination index based on 4 components of the urokinase-type plasminogen activator system].
Bouchet C; Hacène K; Martin PM; Becette V; Tubiana-Hulin M; Lasry S; Oglobine J; Spyratos F
Pathol Biol (Paris); 2000 Nov; 48(9):825-31. PubMed ID: 11141918
[TBL] [Abstract][Full Text] [Related]
18. Estrogen and progesterone receptors status in Thai female breast cancer patients: an analysis of 399 cases at King Chulalongkorn Memorial Hospital.
Lertsanguansinchai P; Chottetanaprasith T; Chatamra K; Sampatanukul P; Wannakrairot P; Rojpornpradit P; Shotelersuk K; Lertbutsayanukul C; Boonjunwetwat D; Vajragupta L
J Med Assoc Thai; 2002 Jun; 85 Suppl 1():S193-202. PubMed ID: 12188412
[TBL] [Abstract][Full Text] [Related]
19. Nonlinear discriminant analysis and prognostic factor classification in node-negative primary breast cancer using probabilistic neural networks.
Le Goff JM; Lavayssière L; Rouëssé J; Spyratos F
Anticancer Res; 2000; 20(3B):2213-8. PubMed ID: 10928180
[TBL] [Abstract][Full Text] [Related]
20. Increased expression of urokinase-type plasminogen activator mRNA determines adverse prognosis in ErbB2-positive primary breast cancer.
Urban P; Vuaroqueaux V; Labuhn M; Delorenzi M; Wirapati P; Wight E; Senn HJ; Benz C; Eppenberger U; Eppenberger-Castori S
J Clin Oncol; 2006 Sep; 24(26):4245-53. PubMed ID: 16963728
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
